Fresenius Kabi announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Tyenne® (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra®* (tocilizumab). Tyenne® becomes the first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA. In accordance with its patent settlement agreement with Genentech, Fresenius Kabi has a license to market its tocilizumab product in the U.S. commencing on the license dates, which are confidential.
Tyenne® is Fresenius Kabi’s third approved U.S. biosimilar and another landmark in the company’s growth strategy towards #FutureFresenius. Recent launches were Tyenne® to treat inflammatory and autoimmune diseases in the EU as well as Idacio® and Stimufend®, expanding treatment options for autoimmune diseases and cancer in the U.S.
* Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. The introduction adds another life-saving treatment to Fresenius Kabi’s broad oncology portfolio that offers lower-cost options for treating a wide range of cancers.
For more information, please see the website of Fresenius Kabi.
Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. The introduction adds another life-saving treatment to Fresenius Kabi’s broad oncology portfolio that offers lower-cost options for treating a wide range of cancers.
For more information, please see the website of Fresenius Kabi.
mAbxience, a Fresenius Kabi majority-owned Group, today announced a CDMO agreement with Biosidus for the manufacture of the ingredient agalsidase beta used in the treatment of Fabry disease. Under the agreement, mAbxience will be responsible for the manufacture of the active ingredient, which is developed by Biosidus as a biosimilar of Fabrazyme®.
This agreement strengthens mAbxience position in the CDMO sector and demonstrates its ability to collaborate in the development and manufacture of complex, high-value treatments.
mAbxience, a Fresenius Kabi majority-owned Group, today announced a CDMO agreement with Biosidus for the manufacture of the ingredient agalsidase beta used in the treatment of Fabry disease. Under the agreement, mAbxience will be responsible for the manufacture of the active ingredient, which is developed by Biosidus as a biosimilar of Fabrazyme®.
This agreement strengthens mAbxience position in the CDMO sector and demonstrates its ability to collaborate in the development and manufacture of complex, high-value treatments.
Fresenius Kabi announced today the immediate availability in the U.S. of Posaconazole Injection, a generic substitute for Noxafil®*, for the treatment or prevention of serious fungal infections. It is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.
For more information, please see the website of Fresenius Kabi.
*Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.
Fresenius Kabi announced today the immediate availability in the U.S. of Posaconazole Injection, a generic substitute for Noxafil®*, for the treatment or prevention of serious fungal infections. It is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.
For more information, please see the website of Fresenius Kabi.
*Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.
mAbxience, a Fresenius Kabi majority-owned Group, today announced a strategic licensing agreement with Intas Pharmaceuticals Ltd for Etanercept biosimilar to target autoimmune diseases. Under the agreement, mAbxience will develop, manufacture, and supply the Etanercept biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP)-approved facilities, and Intas will receive the rights to commercialize in more than 150 countries, including Europe and the United States.
This collaboration demonstrates mAbxience’s commitment to addressing the pressing need for innovative and affordable treatment options for autoimmune diseases.
mAbxience, a Fresenius Kabi majority-owned Group, today announced a strategic licensing agreement with Intas Pharmaceuticals Ltd for Etanercept biosimilar to target autoimmune diseases. Under the agreement, mAbxience will develop, manufacture, and supply the Etanercept biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP)-approved facilities, and Intas will receive the rights to commercialize in more than 150 countries, including Europe and the United States.
This collaboration demonstrates mAbxience’s commitment to addressing the pressing need for innovative and affordable treatment options for autoimmune diseases.
Fresenius Kabi announced today it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona, and Florida. This is the largest contract for Ivenix pumps Fresenius Kabi has signed to date, testament of the stringent implementation of the company’s Vision 2026 strategy.